Європейський Союз - хорватська - EMA (European Medicines Agency)

viatris limited - inzulin glargin - Šećerna bolest - lijekovi koji se koriste u dijabetesu - liječenje dijabetes melitusa kod odraslih, adolescenata i djece u dobi od 2 godine i više.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psorijatični arthritiscosentyx, odvojeno ili u kombinaciji sa metotreksatom (mtx), propisan za liječenje aktivnog psorijatični artritis kod odraslih pacijenata, kada je odgovor na prethodna bolest дорабатывая anti-reumatskih lijekovi (dmards) terapija je bila neadekvatna.. Аксиальный спондилоартрит (axspa)ankilozantni спондилоартрит (kao, радиографические osi спондилоартрит)cosentyx indiciran za liječenje aktivnog анкилозирующего спондилита kod odraslih, koji su adekvatno odgovorili na standardnu terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije. copalia indiciran kod pacijenata kod kojih je krvni pritisak nije dovoljno prati na amlodipin ili валсартан kao monoterapija.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - zastoj srca - antagonisti angiotenzina ii, druge kombinacije, agenti koji djeluju na ренин-ангиотензиновую sustav - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije. exforge indiciran kod pacijenata kod kojih je krvni pritisak nije dovoljno prati na amlodipin ili валсартан kao monoterapija.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - zastoj srca - sredstva koja djeluju na sustav renin-angiotenzina - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - nateglinid - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - nateglinid je indiciran za kombiniranu terapiju metforminom u bolesnika s dijabetesom tipa 2 nedovoljno kontroliranim unatoč maksimalnoj toleriranoj dozi sam metformina.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, тимолола maleat - glaucoma, open-angle; ocular hypertension - ophthalmologicals - smanjenje intraokularnog tlaka (iop) u odraslih bolesnika s otvorenim kutom glaukoma ili očne hipertenzije za koje monoterapija osigurava nedovoljnu redukciju iop.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, metformin hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Європейський Союз - хорватська - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.